SCHEMBL7983771

SCHEMBL7983771

COc1ccc(CN2Cc3c(ccc(C(=O)NC(C)C)c3F)C2=O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 2/20 0.48
HDAC6 Q9UBN7 2/20 0.41
ALDH1A1 P00352 4/20 0.40
MMP1 P03956 1/20 0.39
MMP13 P45452 1/20 0.39
HDAC1 Q13547 2/20 0.39
POLB P06746 1/20 0.39
LMNA P02545 2/20 0.38
CACNA1G O43497 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
CYP2C19 P33261 2/20 0.38
CYP1A2 P05177 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7967987 0.90 IDH1 (0.46) IDH1HDAC6ALDH1A1MMP1MMP13
SCHEMBL7970258 0.88 IDH1 (0.44) IDH1HDAC6ALDH1A1MMP1MMP13
SCHEMBL1418449 0.87 IDH1 (0.47) IDH1HDAC6ALDH1A1MMP1MMP13
SCHEMBL7981153 0.87 IDH1 (0.48) IDH1HDAC6ALDH1A1MMP1MMP13
SCHEMBL7970248 0.81 IDH1 (0.42) IDH1HDAC6ALDH1A1MMP1MMP13
SCHEMBL12810295 0.78 MEN1 (0.39) IDH1ALDH1A1HDAC1LMNASMN1; SMN2
SCHEMBL7981151 0.77 CACNA1G (0.48) IDH1HDAC6ALDH1A1HDAC1POLB
SCHEMBL31159232 0.73 IDH1 (0.52) IDH1ALDH1A1POLBLMNASMN1; SMN2
SCHEMBL30908494 0.70 IDH1 (0.49) IDH1HDAC6ALDH1A1MMP1MMP13
SCHEMBL7979545 0.70 BRD4 (0.45) IDH1HDAC6ALDH1A1MMP1MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed
WO-2010001946-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF アステラス製薬株式会社 (JP) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF HSD11B1, HSD11B2, HSD3B1 IDH1 235/4885HDAC6 532/4885ALDH1A1 359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.